Neurology & Brain Disorders Clinical Trials Update: Week 16, 2026

Published April 17, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

Clinical Trial on Agitation in Alzheimer's Dementia

This Phase 2 trial is testing an oral medication called IGC-AD1, which contains THC, to reduce agitation in people with Alzheimer's dementia. Agitation and aggressive behaviors can be very challenging for patients and their caregivers. If this treatment proves effective, it could provide a new way to improve the quality of life for those living with mild to severe dementia. The study is currently recruiting participants in the US, Canada, and other countries.

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

This Phase 2 study is exploring the use of LHP588, an oral antibacterial drug, for people with mild to moderate Alzheimer's disease who have an infection caused by P. gingivalis bacteria. This infection is thought to play a role in how Alzheimer's progresses. If successful, this treatment might offer a new approach that targets a bacterial cause of the disease. The trial is underway in the United States and requires about 64 weeks of participation, including regular visits and caregiver involvement.

Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease

This Phase 2 trial is testing whether plasma transfusions from donors who regularly exercise can safely improve symptoms in people with early Alzheimer’s disease or mild cognitive impairment. Plasma contains factors that may help brain health, and exercise is known to benefit cognition. If this treatment shows benefit, it could open new possibilities for managing early Alzheimer’s. The study is recruiting adults aged 50 to 75 in Norway.

Fisetin in Mild Alzheimer's Disease

This Phase 2 study is testing fisetin, a natural supplement, in older adults with mild Alzheimer’s disease or mild cognitive impairment. Fisetin is thought to have protective effects on brain cells. If the trial shows it is safe and helpful, fisetin might become an accessible option to support people with early symptoms of Alzheimer’s. The study is currently recruiting a small number of participants in Canada.

Connecting Caregivers With Community Services: The Care Buddy Platform

This study is evaluating a mobile app called Care Buddy designed to support caregivers of people with dementia. The app connects caregivers with community resources and healthcare providers to help reduce the stress of caregiving and improve their knowledge. If shown to be effective, this tool could make a meaningful difference in day-to-day support for caregivers. The trial is recruiting in Singapore with a planned enrollment of 210 participants.

The field of neurology and brain disorders continues to explore a variety of approaches for Alzheimer’s disease and dementia, from new medications targeting symptoms and causes to tools supporting caregivers. Advances in these areas offer hope for improved quality of life for patients and families. Ongoing trials around the world are critical for finding effective treatments and support strategies.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.